Abstracts Archive - Page 1408 of 2607 - ACR Meeting Abstracts

Abstract Number: 311 • 2017 ACR/ARHP Annual Meeting
Total Ankle Arthroplasty for Rheumatoid Arthritis Cases in This Biologics Era: Mid to Long-Term Follow-up
Makoto Hirao¹, Jun Hashimoto², Hideki Tsuboi³, Kosuke Ebina⁴ and Hideki Yoshikawa⁵, ¹Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ²Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ³Orthopaedics/Rheumatology, Osaka Rosai Hospital, Sakai, Japan, ⁴Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan, ⁵Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Outcomes after total ankle arthroplasty (TAA) combined with additive techniques (augmentation of bone strength, control of soft tissue balance, adjustment of the loading axis)…
Abstract Number: 312 • 2017 ACR/ARHP Annual Meeting
Rates of Total Joint Replacement Utilization in the U.S.: Future Projections to 2020-2040 Using the National Inpatient Sample
Jasvinder A. Singh and Shaohua Yu, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To project the future utilization of total hip and knee joint arthroplasty (THA, TKA).Methods: We used the 2000-2010 U.S. National Inpatient Sample combined with…
Abstract Number: 313 • 2017 ACR/ARHP Annual Meeting
The Effect of Obesity on Walking; Comparison of the Spatiotemporal, Kinematic and Kinetic Parameters of Young Obese and Non-Obese Healthy Women
Erkan Kilic¹, Gamze Kilic² and Fatma Inanici³, ¹Rheumatology Clinic, Afyonkarahisar State Hospital, Afyon, Turkey, ²Pyhsical Medicine and Rehabilitation, Afyon Kocatepe University, Faculty of Medicine, Afyon, Turkey, ³Pyhsical Medicine and Rehabilitation, Hacettepe University, Faculty of Medicine, Ankara, Turkey
Background/Purpose: Obesity is a risk factor for development of knee osteoarthritis due to altered gait biomechanics. Gait analysis was performed mostly on older obese adults…
Abstract Number: 314 • 2017 ACR/ARHP Annual Meeting
Effects of Exercise on Anxiety in Adults with Arthritis: A Systematic Review with Meta-Analysis
George Kelley¹, Kristi Kelley¹ and Leigh F. Callahan², ¹Biostatistics, West Virginia University, Morgantown, WV, ²Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Previous randomized controlled trials have led to conflicting findings regarding the effects of exercise on anxiety in adults with arthritis and other rheumatic diseases…
Abstract Number: 315 • 2017 ACR/ARHP Annual Meeting
Efficacy of a Wearable-Enabled Physical Activity Counselling Program for People with Knee Osteoarthritis
Linda Li¹, Eric C. Sayre², Navi Grewal², Juliane Chien², Greg Noonan³, Ryan Falck¹, John Best⁴, Teresa Liu-Ambrose¹, Alison Hoens⁵, Valerie Gray⁶, Karen Tsui⁷, Wendy Watson⁶ and Lynne Feehan⁸, ¹Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Mary Pack Arthritis Program, Vancouver General Hospital, Vancouver, BC, Canada, ⁴University of British Columbia, vancouver, BC, Canada, ⁵BC SUPPORT Unit, Vancouver, BC, Canada, ⁶OASIS Program, Vancouver Coastal Health Authority, Vancouver, BC, Canada, ⁷Fraser Health Authority, Surrey, BC, Canada, ⁸Rehabilitation Program, Fraser Health Authority, Surrey, BC, Canada
Background/Purpose: Current guidelines emphasize an active lifestyle in the management of knee osteoarthritis (OA), but up to 90% of OA patients are inactive. Several modifiable…
Abstract Number: 316 • 2017 ACR/ARHP Annual Meeting
Pain, Fatigue and Function in Patients with Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorder – Relationship with Perceived Benefits and Barriers to Exercise
Leslie Soever¹, Laura Passalent², Ahmed Omar³ and Medha Soowamber⁴, ¹Toronto General Hospital, Toronto, ON, Canada, ²Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada
Background/Purpose: The Ehlers-Danlos Syndromes (EDS) are a heritable group of connective tissue disorders with predominant features including joint hypermobility, skin hyperextensibility and tissue fragility. Hypermobility…
Abstract Number: 317 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Blood Transfusions Following Total Joint Arthroplasty in Patients with Rheumatoid Arthritis
Elizabeth Salt¹, Andrew Johannemann¹, Amanda T. Wiggins², Mary Kay Rayens³, Katelyn Brown¹, Kate Ekmann¹ and Leslie Crofford⁴, ¹University of Kentucky, Lexington, KY, ²Nursing, University of Kentucky, Lexington, KY, ³College of Nursing, University of Kentucky, Lexington, KY, ⁴Rheumatology, Vanderbilt University School of Medicine, Nashville, TN
Risk Factors for Blood Transfusions Following Total Joint Arthroplasty in Patients with Rheumatoid ArthritisAbstractBackground/Purpose: Despite effective therapies, rheumatoid arthritis (RA) can result in joint destruction…
Abstract Number: 318 • 2017 ACR/ARHP Annual Meeting
A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
Kenneth Saag¹, Jeffrey Petersen², Maria Luisa Brandi³, Andrew Karaplis⁴, Mattias Lorentzon⁵, Thierry Thomas⁶, Judy Maddox², Michelle Fan², Paul D. Meisner⁷ and Andreas Grauer², ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³University of Florence, Florence, Italy, ⁴McGill University, Montreal, QC, Canada, ⁵University of Gothenburg and Sahlgrenska University Hospital, Mölndal, Sweden, ⁶CHU de Saint-Étienne, Saint-Étienne, France, ⁷UCB Pharma, Brussels, Belgium
Background/Purpose: The bone forming agent romosozumab (Romo) was previously shown to reduce vertebral and clinical fractures in postmenopausal women with osteoporosis. Here we report the…
Abstract Number: 319 • 2017 ACR/ARHP Annual Meeting
The Placebo-Controlled Fracture Study in Postmenopausal Women with Osteoporosis: The Foundation Effect of Rebuilding Bone with One Year of Romosozumab Leads to Continued Lower Fracture Risk after Transition to Denosumab
Felicia Cosman¹, Daria B Crittenden², Serge Ferrari³, Aliya Khan⁴, Nancy E Lane⁵, Kurt Lippuner⁶, Toshio Matsumoto⁷, Cassandra E Milmont², Cesar Libanati⁸ and Andreas Grauer², ¹Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Geneva University Hospital, Geneva, Switzerland, ⁴McMaster University, Hamilton, ON, Canada, ⁵UC Davis Medical Center, Sacramento, CA, ⁶Osteoporosis Policlinic, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland, ⁷University of Tokushima, Tokushima, Japan, ⁸UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo), a sclerostin antibody, has a dual effect of increasing bone formation and decreasing bone resorption. In the FRAME study, one year of…
Abstract Number: 320 • 2017 ACR/ARHP Annual Meeting
Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial
Cristiano A.F Zerbini¹, Piet Geusens², Eric Lespessailles³, Jean-Jacques Body⁴, Enrique Casado⁵, Jan Stepan⁶, David L Kendler⁷, Luis Russo⁸, Susan L. Greenspan⁹, Salvatore Minisola¹⁰, Alicia Bagur¹¹, Peter Lakatos¹², Astrid Fahrleitner-Pammer¹³, Rüdiger Möricke¹⁴, Pedro Lopez-Romero¹⁵ and Fernando Marin¹⁶, ¹Centro Paulista de Investigações Clinicas, São Paulo, Brazil, ²Maastricht University Hospital, Maastricht, Netherlands, ³Service de Rhumatologie, CHR d'Orléans, Orléans, France, ⁴CHU Brugmann, Free University Brussels, Brussels, Belgium, ⁵Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ⁶Institute of Rheumatology, Faculty of Medicine 1, Charles University, Prague, Czech Republic, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Centro de Analises e Pesquisas Clínicas LTDA,, Rio de Janeiro, Brazil, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Internal Medicine, Policlinico Umberto I,, Rome, Italy, ¹¹Centro de Osteopatías Comlit, Buenos Aires, Argentina, ¹²Department of Medicine, Semmelweis University, Budapest, Hungary, ¹³Division of Endocrinology, Medical University, Graz, Austria, ¹⁴Institut Präventive Medizin & Klinische Forschung, Magdeburg, Germany, ¹⁵Europe Research Center, Eli Lilly and Company, Madrid, Spain, ¹⁶Lilly Research Center Europe, Madrid, Spain
Background/Purpose: The VERO trial was an active-controlled fracture endpoint clinical trial that recruited postmenopausal women with low bone mass and prevalent vertebral fractures (VFx). We…
Abstract Number: 321 • 2017 ACR/ARHP Annual Meeting
A Meta-Analysis of 4 Clinical Trials of Denosumab Compared with Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates
Paul D Miller¹, N Pannacciulli², J Malouf³, A Singer⁴, E Czerwinski⁵, HG Bone⁶, C Wang², Rachel B. Wagman² and JP Brown⁷, ¹Colorado Center for Bone Research, Lakewood, CO, ²Amgen Inc., Thousand Oaks, CA, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Georgetown University Medical Center, Washington, DC, ⁵Krakow Medical Center, Krakow, Poland, ⁶Michigan Bone and Mineral Clinic, Detroit, MI, ⁷CHU de Québec Research Centre and Laval University, Québec, QC, Canada
Background/Purpose: Four clinical trials have separately shown greater BMD gains with transitioning to denosumab (DMAb) compared with continuing on bisphosphonates (BP) in subjects previously treated…
Abstract Number: 322 • 2017 ACR/ARHP Annual Meeting
Safety of Denosumab in a Monocentric Cohort of Kidney Transplant Recipients
Sonia Doddoli, Pierre Lafforgue and Thao Pham, Rheumatology, APHM, Aix Marseille Univ, Marseille, France
Background/Purpose: Safety of denosumab, a fully human monoclonal antibody against RANKL developed for osteoporosis and prevention of fracture remains unclear in kidney transplanted patients. A…
Abstract Number: 323 • 2017 ACR/ARHP Annual Meeting
Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated for up to 10 Years with Denosumab: Results from a Phase 3 Open-Label Extension Study
Nelson B. Watts¹, John T. Grbic², Neil Binkley³, Peter W. Butler⁴, Xiang Yin⁴, Antoniette Tierney⁴, Rachel B. Wagman⁴ and Michael McClung⁵, ¹Mercy Health, Cincinnati, OH, ²Columbia University, New York, NY, ³University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Oregon Osteoporosis Center, Portland, OR
Background/Purpose: Antiresorptive therapy use is associated with osteonecrosis of the jaw (ONJ), an infrequent but serious adverse event. Positively adjudicated ONJ in the denosumab (DMAb)…
Abstract Number: 324 • 2017 ACR/ARHP Annual Meeting
The Predictors of the Efficacy of Denosumab, a Monoclonal Antibody to RANK Ligand, on Osteoporosis in Rheumatoid Arthritis Patients from Japanese Multicenter Study
Kyosuke Hattori¹, Yuji Hirano¹, Yasuhide Kanayama², Nobunori Takahashi³, Naoki Ishiguro³ and Toshihisa Kojima³, ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Although early intensive treatment has improved medication of rheumatoid arthritis (RA), treatment for osteoporosis (OP) in RA patient will be more important. Here, we…
Abstract Number: 325 • 2017 ACR/ARHP Annual Meeting
Zoledronic Acid Did Not Impaired Renal Function in Patients with Osteoporosis
Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan
Background/Purpose: Bisphosphonates are recommended for patients with osteoporosis, however concerns have been raised with regards to their effect on kidney function. The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].